Cannabinoid receptor type-1: Breaking the dogmas.

F1000Research

Volumn 5, Issue , 2016, Pages

  Garcia, Arnau Busquets ^a,b   Soria Gomez, Edgar ^a,b   Bellocchio, Luigi ^a,b   Marsicano, Giovanni ^a,b  

^a INSTITUT FRANÇOIS MAGENDIE   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; CANNABIDIOL; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; LIPOXIN A; PEPCAN 12; PREGNENOLONE; RIMONABANT; UNCLASSIFIED DRUG; ZCZ 011;

ACETYLCHOLINE RELEASE; ALLOSTERISM; DOPAMINE RELEASE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; IN VIVO STUDY; NEUROPATHIC PAIN; OXIDATIVE PHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION;

EID: 85010876776     PISSN: None     EISSN: 20461402     Source Type: Journal    
DOI: 10.12688/F1000RESEARCH.8245.1     Document Type: Review

References (117)

1. Matsuda LA, Lolait SJ, Brownstein MJ, et al.: Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990; 346(6284): 561-4.
2. Howlett AC, Barth F, Bonner TI, et al.: International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev. 2002; 54(2): 161-202.
3. Little PJ, Compton DR, Johnson MR, et al.: Pharmacology and stereoselectivity of structurally novel cannabinoids in mice. J Pharmacol Exp Ther. 1988; 247(3): 1046-51.
4. Devane WA, Hanus L, Breuer A, et al.: Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992; 258(5090): 1946-9.
5. Pacher P, Bátkai S, Kunos G: The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006; 58(3): 389-462.
6. Pertwee RG: Endocannabinoids and Their Pharmacological Actions. Handb Exp Pharmacol. 2015; 231: 1-37.
7. Kano M, Ohno-Shosaku T, Hashimotodani Y, et al.: Endocannabinoid-mediated control of synaptic transmission. Physiol Rev. 2009; 89(1): 309-80.
8. Herkenham M, Lynn AB, Johnson MR, et al.: Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci. 1991; 11(2): 563-83.
9. Tsou K, Brown S, Sañudo-Peña MC, et al.: Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience. 1998; 83(2): 393-411.
10. Westlake TM, Howlett AC, Bonner TI, et al.: Cannabinoid receptor binding and messenger RNA expression in human brain: an in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer's brains. Neuroscience. 1994; 63(3): 637-52.
11. Hu SS, Mackie K: Distribution of the Endocannabinoid System in the Central Nervous System. Handb Exp Pharmacol. 2015; 231: 59-93.
12. Freund TF, Katona I, Piomelli D: Role of endogenous cannabinoids in synaptic signaling. Physiol Rev. 2003; 83(3): 1017-66.
13. Katona I, Freund TF: Multiple functions of endocannabinoid signaling in the brain. Annu Rev Neurosci. 2012; 35: 529-58.
14. Heifets BD, Castillo PE: Endocannabinoid signaling and long-term synaptic plasticity. Annu Rev Physiol. 2009; 71: 283-306.
15. Mechoulam R, Parker LA: The endocannabinoid system and the brain. Annu Rev Psychol. 2013; 64: 21-47.
16. Lu H, Mackie K: An Introduction to the Endogenous Cannabinoid System. Biol Psychiatry. 2016; 79(7): 516-25.
17. Lutz B, Marsicano G, Maldonado R, et al.: The endocannabinoid system in guarding against fear, anxiety and stress. Nat Rev Neurosci. 2015; 16(12): 705-18.
18. Busquets-Garcia A, Desprez T, Metna-Laurent M, et al.: Dissecting the cannabinergic control of behavior: The where matters. Bioessays. 2015; 37(11): 1215-25.
19. Ohno-Shosaku T, Tanimura A, Hashimotodani Y, et al.: Endocannabinoids and retrograde modulation of synaptic transmission. Neuroscientist. 2012; 18(2): 119-32.
20. Bacci A, Huguenard JR, Prince DA: Long-lasting self-inhibition of neocortical interneurons mediated by endocannabinoids. Nature. 2004; 431(7006): 312-6.
21. Min R, Testa-Silva G, Heistek TS, et al.: Diacylglycerol lipase is not involved in depolarization-induced suppression of inhibition at unitary inhibitory connections in mouse hippocampus. J Neurosci. 2010; 30(7): 2710-5.
22. Marinelli S, Pacioni S, Bisogno T, et al.: The endocannabinoid 2-arachidonoylglycerol is responsible for the slow self-inhibition in neocortical interneurons. J Neurosci. 2008; 28(50): 13532-41.
23. Marinelli S, Pacioni S, Cannich A, et al.: Self-modulation of neocortical pyramidal neurons by endocannabinoids. Nat Neurosci. 2009; 12(12): 1488-90.
24. Maroso M, Szabo GG, Kim HK, et al.: Cannabinoid Control of Learning and Memory through HCN Channels. Neuron. 2016; 89(5): 1059-73.
25. Soria-Gómez E, Bellocchio L, Reguero L, et al.: The endocannabinoid system controls food intake via olfactory processes. Nat Neurosci. 2014; 17(3): 407-15.
26. Marsicano G, Lutz B: Neuromodulatory functions of the endocannabinoid system. J Endocrinol Invest. 2006; 29(3 Suppl): 27-46.
27. Kawamura Y, Fukaya M, Maejima T, et al.: The CB1 cannabinoid receptor is the major cannabinoid receptor at excitatory presynaptic sites in the hippocampus and cerebellum. J Neurosci. 2006; 26(11): 2991-3001.
28. Häring M, Enk V, Aparisi Rey A, et al.: Cannabinoid type-1 receptor signaling in central serotonergic neurons regulates anxiety-like behavior and sociability. Front Behav Neurosci. 2015; 9: 235.
29. Hernandez G, Cheer JF: To Act or Not to Act: Endocannabinoid/Dopamine Interactions in Decision-Making. Front Behav Neurosci. 2015; 9: 336.
30. Martin HG, Bernabeu A, Lassalle O, et al.: Endocannabinoids Mediate Muscarinic Acetylcholine Receptor-Dependent Long-Term Depression in the Adult Medial Prefrontal Cortex. Front Cell Neurosci. 2015; 9: 457.
31. Soria-Gómez E, Busquets-Garcia A, Hu F, et al.: Habenular CB1 Receptors Control the Expression of Aversive Memories. Neuron. 2015; 88(2): 306-13.
32. Mackie K: Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb Exp Pharmacol. 2005; (168): 299-325.
33. Katona I: Cannabis and Endocannabinoid Signaling in Epilepsy. Handb Exp Pharmacol. 2015; 231: 285-316.
34. Bellocchio L, Lafenêtre P, Cannich A, et al.: Bimodal control of stimulated food intake by the endocannabinoid system. Nat Neurosci. 2010; 13(3): 281-3.
35. Rey AA, Purrio M, Viveros MP, et al.: Biphasic effects of cannabinoids in anxiety responses: CB1 and GABAB receptors in the balance of GABAergic and glutamatergic neurotransmission. Neuropsychopharmacology. 2012; 37(12): 2624-34.
36. Dubreucq S, Durand A, Matias I, et al.: Ventral tegmental area cannabinoid type-1 receptors control voluntary exercise performance. Biol Psychiatry. 2013; 73(9): 895-903.
37. Fuss J, Steinle J, Bindila L, et al.: A runner's high depends on cannabinoid receptors in mice. Proc Natl Acad Sci U S A. 2015; 112(42): 13105-8.
38. Martín-García E, Bourgoin L, Cathala A, et al.: Differential Control of Cocaine Self-Administration by GABAergic and Glutamatergic CB1 Cannabinoid Receptors. Neuropsychopharmacology. 2015.
39. Talani G, Lovinger DM: Interactions between ethanol and the endocannabinoid system at GABAergic synapses on basolateral amygdala principal neurons. Alcohol. 2015; 49(8): 781-94.
40. Albayram ö, Passlick S, Bilkei-Gorzo A, et al.: Physiological impact of CB1 receptor expression by hippocampal GABAergic interneurons. Pflugers Arch. 2016; 468(4): 727-37.
41. Puighermanal E, Marsicano G, Busquets-Garcia A, et al.: Cannabinoid modulation of hippocampal long-term memory is mediated by mTOR signaling. Nat Neurosci. 2009; 12(9): 1152-8.
42. Chiarlone A, Bellocchio L, Blázquez C, et al.: A restricted population of CB1 cannabinoid receptors with neuroprotective activity. Proc Natl Acad Sci U S A. 2014; 111(22): 8257-62.
43. Metna-Laurent M, Soria-Gómez E, Verrier D, et al.: Bimodal control of fear-coping strategies by CB1 cannabinoid receptors. J Neurosci. 2012; 32(21): 7109-18.
44. Terzian AL, Micale V, Wotjak CT: Cannabinoid receptor type 1 receptors on GABAergic vs. glutamatergic neurons differentially gate sex-dependent social interest in mice. Eur J Neurosci. 2014; 40(1): 2293-8.
45. Dubreucq S, Matias I, Cardinal P, et al.: Genetic dissection of the role of cannabinoid type-1 receptors in the emotional consequences of repeated social stress in mice. Neuropsychopharmacology. 2012; 37(8): 1885-900.
46. Han J, Kesner P, Metna-Laurent M, et al.: Acute cannabinoids impair working memory through astroglial CB1 receptor modulation of hippocampal LTD. Cell. 2012; 148(5): 1039-50.
47. Molina-Holgado E, Vela JM, Arévalo-Martín A, et al.: Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling. J Neurosci. 2002; 22(22): 9742-53.
48. Stella N: Endocannabinoid signaling in microglial cells. Neuropharmacology. 2009; 56(Suppl 1): 244-53.
49. Mecha M, Feliú A, Carrillo-Salinas FJ, et al.: Endocannabinoids drive the acquisition of an alternative phenotype in microglia. Brain Behav Immun. 2015; 49: 233-45.
50. Oliveira da Cruz JF, Robin LM, Drago F, et al.: Astroglial type-1 cannabinoid receptor (CB1): A new player in the tripartite synapse. Neuroscience. 2016; 323: 35-42.
51. Metna-Laurent M, Marsicano G: Rising stars: modulation of brain functions by astroglial type-1 cannabinoid receptors. Glia. 2015; 63(3): 353-64.
52. Navarrete M, Díez A, Araque A: Astrocytes in endocannabinoid signalling. Philos Trans R Soc Lond B Biol Sci. 2014; 369(1654): 20130599.
53. Pérez-Alvarez A, Araque A: Astrocyte-neuron interaction at tripartite synapses. Curr Drug Targets. 2013; 14(11): 1220-4.
54. Martín R, Bajo-Grañeras R, Moratalla R, et al.: Circuit-specific signaling in astrocyte-neuron networks in basal ganglia pathways. Science. 2015; 349(6249): 730-4.
55. Oliveira JF, Sardinha VM, Guerra-Gomes S, et al.: Do stars govern our actions? Astrocyte involvement in rodent behavior. Trends Neurosci. 2015; 38(9): 535-49.
56. Dudok B, Barna L, Ledri M, et al.: Cell-specific STORM super-resolution imaging reveals nanoscale organization of cannabinoid signaling. Nat Neurosci. 2015; 18(1): 75-86.
57. Thibault K, Carrel D, Bonnard D, et al.: Activation-dependent subcellular distribution patterns of CB1 cannabinoid receptors in the rat forebrain. Cereb Cortex. 2013; 23(11): 2581-91.
58. Bénard G, Massa F, Puente N, et al.: Mitochondrial CB1 receptors regulate neuronal energy metabolism. Nat Neurosci. 2012; 15(4): 558-64.
59. Howlett AC: The cannabinoid receptors. Prostaglandins Other Lipid Mediat. 2002; 68-69: 619-31.
60. Bartova A, Birmingham MK: Effect of delta9-tetrahydrocannabinol on mitochondrial NADH-oxidase activity. J Biol Chem. 1976; 251(16): 5002-6.
61. Aquila S, Guido C, Santoro A, et al.: Rimonabant (SR141716) induces metabolism and acquisition of fertilizing ability in human sperm. Br J Pharmacol. 2010; 159(4): 831-41.
62. Arrabal S, Lucena MA, Canduela MJ, et al.: Pharmacological Blockade of Cannabinoid CB1 Receptors in Diet-Induced Obesity Regulates Mitochondrial Dihydrolipoamide Dehydrogenase in Muscle. PLoS One. 2015; 10(12): e0145244.
63. Vallée M, Vitiello S, Bellocchio L, et al.: Pregnenolone can protect the brain from cannabis intoxication. Science. 2014; 343(6166): 94-8.
64. Hebert-Chatelain E, Reguero L, Puente N, et al.: Cannabinoid control of brain bioenergetics: Exploring the subcellular localization of the CB1 receptor. Mol Metab. 2014; 3(4): 495-504.
65. Koch M, Varela L, Kim JG, et al.: Hypothalamic POMC neurons promote cannabinoid-induced feeding. Nature. 2015; 519(7541): 45-50.
66. Hollis F, van der Kooij MA, Zanoletti O, et al.: Mitochondrial function in the brain links anxiety with social subordination. Proc Natl Acad Sci U S A. 2015; 112(50): 15486-91.
67. Cota D, Marsicano G, Tschöp M, et al.: The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest. 2003; 112(3): 423-31.
68. Izzo AA, Sharkey KA: Cannabinoids and the gut: new developments and emerging concepts. Pharmacol Ther. 2010; 126(1): 21-38.
69. Jyotaki M, Shigemura N, Ninomiya Y: Modulation of sweet taste sensitivity by orexigenic and anorexigenic factors. Endocr J. 2010; 57(6): 467-75.
70. Nadolska K, Gos R: [The role of endocannabinoid system in physiological and pathological processes in the eye]. Klin Oczna. 2008; 110(10-12): 392-6.
71. Mach F, Steffens S: The role of the endocannabinoid system in atherosclerosis. J Neuroendocrinol. 2008; 20(Suppl 1): 53-7.
72. Osei-Hyiaman D, DePetrillo M, Pacher P, et al.: Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest. 2005; 115(5): 1298-305.
73. Cota D: CB1 receptors: emerging evidence for central and peripheral mechanisms that regulate energy balance, metabolism, and cardiovascular health. Diabetes Metab Res Rev. 2007; 23(7): 507-17.
74. Jean-Gilles L, Braitch M, Latif ML, et al.: Effects of pro-inflammatory cytokines on cannabinoid CB1 and CB2 receptors in immune cells. Acta Physiol (Oxf). 2015; 214(1): 63-74.
75. Idris AI, van't Hof RJ, Greig IR, et al.: Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nat Med. 2005; 11(7): 774-9.
76. Bíró T, Tóth BI, Haskó G, et al.: The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities. Trends Pharmacol Sci. 2009; 30(8): 411-20.
77. Cavuoto P, McAinch AJ, Hatzinikolas G, et al.: The expression of receptors for endocannabinoids in human and rodent skeletal muscle. Biochem Biophys Res Commun. 2007; 364(1): 105-10.
78. Maccarrone M, Bab I, Bíró T, et al.: Endocannabinoid signaling at the periphery: 50 years after THC. Trends Pharmacol Sci. 2015; 36(5): 277-96.
79. Bellocchio L, Soria-Gómez E, Quarta C, et al.: Activation of the sympathetic nervous system mediates hypophagic and anxiety-like effects of CB1 receptor blockade. Proc Natl Acad Sci U S A. 2013; 110(12): 4786-91.
80. Hofer SC, Ralvenius WT, Gachet MS, et al.: Localization and production of peptide endocannabinoids in the rodent CNS and adrenal medulla. Neuropharmacology. 2015; 98: 78-89.
81. Cani PD, Plovier H, Van Hul M, et al.: Endocannabinoids-at the crossroads between the gut microbiota and host metabolism. Nat Rev Endocrinol. 2016; 12(3): 133-43.
82. Geurts L, Everard A, Van Hul M, et al.: Adipose tissue NAPE-PLD controls fat mass development by altering the browning process and gut microbiota. Nat Commun. 2015; 6: 6495.
83. Vemuri VK, Makriyannis A: Medicinal chemistry of cannabinoids. Clin Pharmacol Ther. 2015; 97(6): 553-8.
84. Pertwee RG: GPR55: a new member of the cannabinoid receptor clan? Br J Pharmacol. 2007; 152(7): 984-6.
85. Lauckner JE, Jensen JB, Chen HY, et al.: GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci U S A. 2008; 105(7): 2699-704.
86. Xiong W, Cui T, Cheng K, et al.: Cannabinoids suppress inflammatory and neuropathic pain by targeting a3 glycine receptors. J Exp Med. 2012; 209(6): 1121-34.
87. Di Marzo V, De Petrocellis L: Why do cannabinoid receptors have more than one endogenous ligand? Philos Trans R Soc Lond B Biol Sci. 2012; 367(1607): 3216-28.
88. Christensen R, Kristensen PK, Bartels EM, et al.: Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet. 2007; 370(9600): 1706-13.
89. Volkow ND, Baler RD, Compton WM, et al.: Adverse health effects of marijuana use. N Engl J Med. 2014; 370(23): 2219-27.
90. Janero DR: Cannabinoid-1 receptor (CB1R) blockers as medicines: beyond obesity and cardiometabolic disorders to substance abuse/drug addiction with CB1R neutral antagonists. Expert Opin Emerg Drugs. 2012; 17(1): 17-29.
91. Whiting PF, Wolff RF, Deshpande S, et al.: Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA. 2015; 313(24): 2456-73.
92. Gentry PR, Sexton PM, Christopoulos A: Novel Allosteric Modulators of G Protein-coupled Receptors. J Biol Chem. 2015; 290(32): 19478-88.
93. van der Westhuizen ET, Valant C, Sexton PM, et al.: Endogenous allosteric modulators of G protein-coupled receptors. J Pharmacol Exp Ther. 2015; 353(2): 246-60.
94. Price MR, Baillie GL, Thomas A, et al.: Allosteric modulation of the cannabinoid CB1 receptor. Mol Pharmacol. 2005; 68(5): 1484-95.
95. Horswill JG, Bali U, Shaaban S, et al.: PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats. Br J Pharmacol. 2007; 152(5): 805-14.
96. Navarro HA, Howard JL, Pollard GT, et al.: Positive allosteric modulation of the human cannabinoid (CB) receptor by RTI-371, a selective inhibitor of the dopamine transporter. Br J Pharmacol. 2009; 156(7): 1178-84.
97. Abood ME: Allosteric Modulators: A Side Door. J Med Chem. 2016; 59(1): 42-3.
98. Morales P, Goya P, Jagerovic N, et al.: Allosteric Modulators of the CB1 Cannabinoid Receptor: A Structural Update Review. Cannabis and Cannabinoid Research. 2016; 1(1): 22-30.
99. Ignatowska-Jankowska BM, Baillie GL, Kinsey S, et al.: A Cannabinoid CB1 Receptor-Positive Allosteric Modulator Reduces Neuropathic Pain in the Mouse with No Psychoactive Effects. Neuropsychopharmacology. 2015; 40(13): 2948-59.
100. Pamplona FA, Ferreira J, Menezes de Lima O Jr, et al.: Anti-inflammatory lipoxin A4 is an endogenous allosteric enhancer of CB1 cannabinoid receptor. Proc Natl Acad Sci U S A. 2012; 109(51): 21134-9.
101. Laprairie RB, Bagher AM, Kelly ME, et al.: Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol. 2015; 172(20): 4790-805.
102. Hill AJ, Williams CM, Whalley BJ, et al.: Phytocannabinoids as novel therapeutic agents in CNS disorders. Pharmacol Ther. 2012; 133(1): 79-97.
103. Chiodi V, Ferrante A, Ferraro L, et al.: Striatal adenosine-cannabinoid receptor interactions in rats over-expressing adenosine A2A receptors. J Neurochem. 2016; 136(5): 907-17.
104. Viñals X, Moreno E, Lanfumey L, et al.: Cognitive Impairment Induced by Delta9-tetrahydrocannabinol Occurs through Heteromers between Cannabinoid CB1 and Serotonin 5-HT2A Receptors. PLoS Biol. 2015; 13(7): e1002194.
105. Callén L, Moreno E, Barroso-Chinea P, et al.: Cannabinoid receptors CB1 and CB2 form functional heteromers in brain. J Biol Chem. 2012; 287(25): 20851-65.
106. Maccarrone M, Bernardi G, Agrò AF, et al.: Cannabinoid receptor signalling in neurodegenerative diseases: a potential role for membrane fluidity disturbance. Br J Pharmacol. 2011; 163(7): 1379-90.
107. Lee SH, Ledri M, Tóth B, et al.: Multiple Forms of Endocannabinoid and Endovanilloid Signaling Regulate the Tonic Control of GABA Release. J Neurosci. 2015; 35(27): 10039-57.
108. Zhang HY, Gao M, Shen H, et al.: Expression of functional cannabinoid CB2 receptor in VTA dopamine neurons in rats. Addict Biol. 2016.
109. Li Y, Kim J: CB2 Cannabinoid Receptor Knockout in Mice Impairs Contextual Long-Term Memory and Enhances Spatial Working Memory. Neural Plast. 2016; 2016: 9817089.
110. Li Y, Kim J: Deletion of CB2 cannabinoid receptors reduces synaptic transmission and long-term potentiation in the mouse hippocampus. Hippocampus. 2016; 26(3): 275-81.
111. Pistis M, Melis M: From surface to nuclear receptors: the endocannabinoid family extends its assets. Curr Med Chem. 2010; 17(14): 1450-67.
112. Fezza F, Bari M, Florio R, et al.: Endocannabinoids, related compounds and their metabolic routes. Molecules. 2014; 19(11): 17078-106.
113. Viader A, Blankman JL, Zhong P, et al.: Metabolic Interplay between Astrocytes and Neurons Regulates Endocannabinoid Action. Cell Rep. 2015; 12(5): 798-808.
114. Viader A, Ogasawara D, Joslyn CM, et al.: A chemical proteomic atlas of brain serine hydrolases identifies cell type-specific pathways regulating neuroinflammation. eLife. 2016; 5: e12345.
115. Steindel F, Lerner R, Häring M, et al.: Neuron-type specific cannabinoidmediated G protein signalling in mouse hippocampus. J Neurochem. 2013; 124(6): 795-807.
116. Bellocchio: Patent: Compositions targeting cb1 receptor for controlling food intake. Application Number: EP09306163.8. European Patent Office. 2010.
117. Di Marzo V, Stella N, Zimmer A: Endocannabinoid signalling and the deteriorating brain. Nat Rev Neurosci. 2015; 16(1): 30-42.